Elanco Animal Health Q2 2024 Adj. EPS $0.30 Beats $0.24 Estimate, Sales $1.020B Miss $1.156B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elanco Animal Health (NYSE:ELAN) reported Q2 2024 adjusted EPS of $0.30, beating the $0.24 estimate by 25%. However, sales of $1.020 billion missed the $1.156 billion estimate by 11.78%. EPS increased by 66.67% year-over-year, while sales decreased by 3.50%.
August 08, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elanco Animal Health reported Q2 2024 adjusted EPS of $0.30, beating estimates by 25%, but sales of $1.020 billion missed estimates by 11.78%. EPS increased by 66.67% year-over-year, while sales decreased by 3.50%.
The mixed results, with EPS beating estimates significantly but sales missing by a notable margin, suggest a neutral short-term impact on the stock price. Investors may be encouraged by the strong EPS growth but concerned about the sales decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100